EYPT · Eyepoint Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $696.0K | - | $966.0K | $5.33M | $24.45M | - | $10.52M | $9.48M | $11.68M | - |
| Cost of Revenue | - | - | - | - | - | - | $1.20M | $1.79M | $759.0K | - |
| Gross Profit | - | - | - | - | - | - | $9.32M | $7.68M | $10.93M | - |
| R&D | $72.15M | - | $47.75M | $55.50M | $58.57M | - | $29.54M | $29.82M | $30.14M | - |
| SG&A | $15.24M | - | $14.49M | $11.86M | $13.88M | - | $12.97M | $12.75M | $14.10M | - |
| Total Operating Expenses | $87.92M | - | $43.27M | $67.56M | $45.01M | - | $29.60M | $31.87M | $45.01M | - |
| D&A | $497.0K | - | $576.0K | $362.0K | $303.0K | - | - | - | $303.0K | - |
| Operating Income | ($87.23M) | - | ($62.02M) | ($62.23M) | ($48.84M) | - | ($32.75M) | ($34.55M) | ($33.32M) | - |
| Interest Expense | - | - | - | - | - | - | - | $0 | $0 | - |
| Income Tax | $0 | - | $0 | $0 | - | - | - | - | - | - |
| Net Income | ($84.83M) | - | ($59.73M) | ($59.43M) | ($45.20M) | - | ($29.36M) | ($30.83M) | ($29.28M) | - |
| EPS - Basic | ($0.99) | - | ($0.85) | ($0.85) | ($0.65) | - | ($0.54) | ($0.58) | ($0.55) | - |
| EPS - Diluted | ($0.99) | - | ($0.85) | ($0.85) | ($0.65) | - | ($0.54) | ($0.58) | ($0.55) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $77.71M | $101.82M | $74.58M | $71.14M | $85.16M | $99.70M | $79.83M | $90.77M | $271.01M | $281.26M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $1.25M | $1.81M | $2.11M | $2.68M | $2.13M | $2.31M | $2.81M | $3.67M | $4.26M | $3.91M |
| Accounts Payable | $18.81M | $10.49M | $10.08M | $19.68M | $16.42M | $11.72M | $7.34M | $14.30M | $7.08M | $6.50M |
| Current Assets | $249.50M | $328.65M | $216.11M | $265.25M | $326.98M | $383.31M | $268.55M | $294.93M | $317.71M | $344.80M |
| Total Assets | $288.22M | $364.00M | $251.69M | $301.15M | $362.56M | $418.46M | $300.92M | $324.25M | $329.25M | $355.18M |
| Current Liabilities | $37.46M | $37.02M | $30.09M | $33.17M | $41.68M | $49.05M | $48.79M | $62.10M | $62.58M | $63.26M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $57.74M | $57.88M | $51.51M | $55.14M | $64.17M | $81.96M | $82.18M | $95.94M | $79.31M | $88.86M |
| Stockholders' Equity | $230.47M | $306.11M | $200.18M | $246.01M | $298.40M | $336.50M | $218.73M | $228.31M | $249.93M | $266.32M |
| Retained Earnings | ($1.19B) | ($1.10B) | ($1.04B) | ($977.64M) | ($918.21M) | ($873.02M) | ($831.62M) | ($802.26M) | ($771.43M) | ($742.15M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($80.55M) | - | - | - | ($53.12M) | - | - | - | ($31.17M) | - |
| Investing Cash Flow | $59.05M | - | - | - | $39.52M | - | - | - | $20.81M | - |
| Financing Cash Flow | ($2.61M) | - | - | - | ($951.0K) | - | - | - | $115.0K | - |
| CapEx | $997.0K | - | - | - | $276.0K | - | - | - | $1.19M | - |
| Free Cash Flow | ($81.55M) | - | - | - | ($53.40M) | - | - | - | ($32.37M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | 88.6% | 81.1% | 93.5% | - |
| Operating margin | -12532.5% | - | -6420.8% | -1166.8% | -199.7% | - | -311.2% | -364.5% | -285.2% | - |
| EBITDA margin | -12461.1% | - | -6361.2% | -1160.0% | -198.5% | - | - | - | -282.6% | - |
| Net margin | -12188.5% | - | -6183.4% | -1114.3% | -184.8% | - | -279.0% | -325.3% | -250.6% | - |
| Free cash flow margin | -11716.4% | - | - | - | -218.4% | - | - | - | -277.0% | - |
| FCF / Net income | 0.96 | - | - | - | 1.18 | - | - | - | 1.11 | - |
| R&D / Revenue | 10366.1% | - | 4943.5% | 1040.7% | 239.5% | - | 280.7% | 314.7% | 258.0% | - |
| SG&A / Revenue | 2190.1% | - | 1500.0% | 222.4% | 56.7% | - | 123.2% | 134.5% | 120.7% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -29.4% | - | -23.7% | -19.7% | -12.5% | - | -9.8% | -9.5% | -8.9% | - |
| Return on equity | -36.8% | - | -29.8% | -24.2% | -15.1% | - | -13.4% | -13.5% | -11.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 6.66 | 8.88 | 7.18 | 8.00 | 7.85 | 7.81 | 5.50 | 4.75 | 5.08 | 5.45 |
| Quick ratio | 6.63 | 8.83 | 7.11 | 7.91 | 7.79 | 7.77 | 5.45 | 4.69 | 5.01 | 5.39 |
| Cash ratio | 2.07 | 2.75 | 2.48 | 2.14 | 2.04 | 2.03 | 1.64 | 1.46 | 4.33 | 4.45 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.25 | 1.19 | 1.26 | 1.22 | 1.22 | 1.24 | 1.38 | 1.42 | 1.32 | 1.33 |
| Liabilities / Assets | 0.20 | 0.16 | 0.20 | 0.18 | 0.18 | 0.20 | 0.27 | 0.30 | 0.24 | 0.25 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.02 | 0.07 | - | 0.03 | 0.03 | 0.04 | - |
| Inventory turnover | - | - | - | - | - | - | 0.43 | 0.49 | 0.18 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | 852d | 748d | 2047d | - |
| Days payable outstanding | - | - | - | - | - | - | 2230d | 2912d | 3406d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.0x | - | 0.0x | 0.0x | 1.3x | - | 2.0x | 2.0x | 0.0x | - |
| P / S | 1.6x | - | 1.0x | 0.1x | 15.5x | - | 41.3x | 48.8x | 0.1x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -97.2% | - | -90.8% | -43.7% | 109.3% | - | -30.8% | 4.1% | 52.1% | - |
| Revenue CAGR (3y) | -55.1% | - | -54.1% | -22.7% | 38.1% | - | 5.1% | 1.7% | 16.9% | - |
| Revenue CAGR (5y) | -37.5% | - | -42.7% | 5.3% | 26.7% | - | 33.2% | 5.6% | 88.9% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -78.6% | - | -89.4% | -80.1% | -46.6% | - | -127.4% | -51.8% | -54.6% | - |
| Net income growth (YoY) | -87.7% | - | -103.4% | -92.8% | -54.3% | - | -132.8% | -34.5% | -38.4% | - |
| EPS growth (YoY) | -52.3% | - | -57.4% | -46.6% | -18.2% | - | -63.6% | 4.9% | 1.8% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -52.7% | - | - | - | -65.0% | - | - | - | -86.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -22.8% | -9.0% | -8.5% | 7.8% | 19.4% | 26.4% | 273.1% | 298.7% | 218.8% | 176.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$61.57M totalLicense And Collaboration Agreement$16.73M · 27.2%
Product Rights Agreement$15.90M · 25.8%
Royalty$13.04M · 21.2%
Royalty Purchase Agreement$12.70M · 20.6%
YUTIQProduct$1.60M · 2.6%
Product$1.60M · 2.6%
Geographic
$31.37M totalUS$29.98M · 95.6%
CN$1.29M · 4.1%
GB$100.0K · 0.3%
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing EyePoint Pharmaceuticals against the 5 most active filers in the same SIC group.